In this issue of Angiology, Ticulescu et al 1 assess the role of arterial stiffness in relation to established risk factors in predicting cardiovascular (CV) remodeling. They assessed left ventricular mass index (LVMi) and carotid intima media thickness (IMT) in patients with moderate renal impairment. Outpatients with stage III chronic kidney disease ([CKD] n ¼ 89) and with stage II CKD (n ¼ 52) underwent echocardiographic and supra-aortic trunk scanning; carotid IMT was measured 1 cm beneath the carotid bifurcation, whereas arterial stiffness was assessed at the right carotid as the b index. 1 As Ticulescu et al 1 point out, this echotracking estimation of arterial stiffness represents a useful and feasible technique that allows the evaluation of both heart and vessels during one examination. 2 The 2 groups were similar for established CV risk factors (ie, age, gender, hypertension, hypercholesterolemia, diabetes mellitus [DM], and smoking) and relevant drug treatment. No significant differences were found in terms of blood pressure, biochemical parameters (except for creatinine clearance), IMT, LVMi, and presence of carotid plaques. 1 After multivariate analysis, the b index of arterial stiffness was an independent predictor of IMT (along with age, DM, and hypercholesterolemia) in patients with stage III CKD; the most powerful predictor was DM, followed by age, b index, and hypercholesterolemia. In the stage II CKD group, DM was the only independent predictor of IMT. 1 As discussed by Ticulescu et al, 1 this finding could reflect the functional effect of arterial wall remodeling at different stages of CKD; the intimal layer plays a main role in atherogenesis during earlier stages of CKD, whereas in more advanced CKD, the atherosclerotic process mainly involves the medial layer.
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Chronic kidney disease is recognized as a CV risk factor, 3 and these patients should be treated accordingly. On the other hand, arterial stiffness, regulated by numerous factors, such as mean arterial pressure, structural alterations of the arterial wall, endothelial dysfunction, and inflammation, may accelerate the atherosclerotic process. 4 There are several different noninvasive methods for the assessment of arterial stiffness including pulse wave velocity (PWV), relating change in vessel diameter (or area) to distending pressure, arterial pulse waveform analysis, ambulatory arterial stiffness index, augmentation index, and b index 2,5 ; PWV is the most recognized and established index of arterial stiffness. 6, 7 Arterial stiffness and CKD are closely linked by shared risk factors and associated increased CV mortality. 8 In a cohort of hemodialysis patients, both carotid IMT and b index of arterial stiffness were independently predictive of CV mortality even after adjustment for other relevant covariates, implicating the distinct roles of stiffness and thickness of arterial wall in the pathogenesis of CV disease. 9 Furthermore, arterial stiffness assessed by aortofemoral PWV was the only arterial index (among carotid IMT, systemic arterial compliance, and carotid-derived augmentation index) independently associated with CV outcome in patients with stages IV and V CKD. 10 It should be noted that arterial stiffness is a predictor for CV events not only in renal patients but also in the general population, in patients with hypertension, impaired glucose intolerance, and coronary artery disease. 11 Furthermore, a recent meta-analysis showed that aortic PWV was a strong predictor of CV events and all-cause mortality in 15 877 individuals; the higher the baseline CV risk, the higher the predictive ability of arterial stiffness. 12 Interestingly, aortic PWV was a stronger independent predictor (r ¼ .48; P ¼ .002) of a 25% decline in renal function or initiation of renal replacement therapy compared with systolic blood pressure (r ¼ .17; P ¼ .039) and urine-proteinto-creatinine ratio (r ¼ .20; P ¼ .021) in patients with stages III and IV CKD. 8 Arterial stiffness correlates with established risk factors. Briefly, both age 13 and male gender 14 are associated with increased arterial stiffness. Furthermore, hypertensive patients have stiffer arteries. 15 Both office and 24-hour blood pressure were reported to be independent predictors of aortic PWV. 16 Diabetes mellitus may accelerate arterial stiffness, even during the pre-diabetic stage. 17, 18 Of note, glycosylated hemoglobin A 1c (HbA 1c ) was an independent determinant of PWV even in nondiabetic hemodialysis patients. 19 Obesity is associated with increased arterial stiffness; possible mechanisms that contribute to this obesity-related impaired arterial compliance include endothelial dysfunction, impaired smooth muscle cell function, insulin resistance, hypercholesterolemia, and hyperleptinaemia. 20 Interestingly, in morbidly obese patients, several markers of obesity (ie, increasing body mass index [BMI], waist circumference, waist-to-hip ratio, visceral fat area, and fat mass) independently correlated with higher PWV in women, but not in men, after adjustment for age, hypertension, and type 2 DM. 21 Weight loss improves CV risk factors and arterial compliance. 20 Of note, in patients with CKD, PWV correlated significantly with systolic blood pressure, DM, and BMI. 22 There is also evidence that smoking may increase arterial stiffness. 23 However, the effect of smoking cessation on this vascular index remains to be established.
Several drugs that reduce CV risk have been shown to improve arterial stiffness. In this context, certain antihypertensive agents (ie, drugs blocking the renin-angiotensin system, combined with a diuretic or a calcium antagonist) were reported to decrease arterial stiffness and/or wave reflections. 24 Of note, this beneficial effect of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers on arterial stiffness in patients with CKD was also associated with improved prognosis. 25 Vasodilator b-blockers were shown to favorably affect central BP and arterial stiffening. 26 In detail, vasodilators decrease the amplitude and increase the travel time (or delay) of the reflected wave, whereas vasoconstrictors can alter arterial stiffness of the muscular arteries by changing PWV of the reflected wave from the periphery to the heart. 27 Interestingly, it has been suggested that the observed disparity in CV events obtained by different antihypertensive drugs might be attributed to their diverse effect on these markers. [28] [29] [30] Anti-inflammatory agents, such as corticosteroids and antitumor necrosis factor-a, and lipid-lowering drugs such as statins have also been shown to reduce arterial stiffness in several patient groups. 4, [31] [32] [33] Similarly, metformin 34 and thiazolidinediones (ie, pioglitazone 35 and rosiglitazone 36 ) may improve arterial compliance in insulin-resistant patients.
We should keep in mind that arterial stiffness, along with central blood pressure and pulse pressure, represents useful CV risk markers, providing an additional prognostic value. Thus, they should be measured in high-risk patients such as those with CKD even in the early stages of the disease. However, in order to ascertain arterial stiffness as a surrogate end point for targeting residual risk and drug development, there is a need to demonstrate that the regression of arterial stiffness is associated with improved CV outcome. 37 Prospective, long-term, large clinical trials are required. Furthermore, a ''gold standard'' technique of measurement and a reference range should be established to facilitate the use of arterial stiffness in daily clinical practice. In this context, a recent study was the first to report reference values for carotid-femoral PWV, combining a sizeable European population after standardizing results for different methods of PWV measurement. 38 However, as data suggest ethnic/racial differences in PWV values, 39 the results of such studies should be interpreted with caution.
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